{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:11Z","timestamp":1787841311504,"version":"build-2784847793"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced disease. Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. Several of these agents, which offer improved targeting, greater potency, and better therapeutic index over traditional chemotherapy, are changing the treatment landscape for lymphomas and other hematological malignancies. Despite the therapeutic potential of these agents, the delivery and release of cytotoxic agents to malignant cells through the combination of a monoclonal antibody, payload, and linker represents a complex design challenge. This article reviews the clinical data on currently available antibody drug conjugates and the ongoing development of novel antibody drug conjugates. Antibody drug conjugates constitute an important armamentarium for treatment of lymphomas and their evolving roles in the treatment spectrum are discussed.<\/jats:p>","DOI":"10.1016\/j.hemonc.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:43:05Z","timestamp":1627450985000},"page":"21-34","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed\/Refractory Lymphomas"],"prefix":"10.4103","volume":"16","author":[{"given":"Hamza","family":"Hashmi","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Medical University of South Carolina, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Darwin","sequence":"additional","affiliation":[{"name":"University of South Florida, Morsani College of Medicine, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"1","key":"R1-20241211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"R2-20241211","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.mpmed.2017.02.003","article-title":"Hodgkin lymphoma","volume":"45","author":"Fields","year":"2017","journal-title":"Medicine."},{"issue":"10091","key":"R3-20241211","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non- hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"The Lancet."},{"issue":"16","key":"R4-20241211","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR- 1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood."},{"issue":"1","key":"R5-20241211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2016.08.001","article-title":"Tumour cell surface antigen targeted therapies in B-cell lymphomas: beyond rituximab","volume":"31","author":"Ku","year":"2017","journal-title":"J Blood Reviews."},{"issue":"27","key":"R6-20241211","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the ritux- imab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"R7-20241211","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"R8-20241211","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2017.1366447","article-title":"Emerging antibody-drug conjugates for treating lymphoid malignancies","volume":"22","author":"Wolska-Washer","year":"2017","journal-title":"Expert Opin Emerging Drugs"},{"issue":"6","key":"R9-20241211","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"R10-20241211","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2011.03.017","article-title":"Antibody-DM1 conjugates as cancer therapeutics","volume":"307","author":"Lopus","year":"2011","journal-title":"Cancer Lett"},{"issue":"6","key":"R11-20241211","first-page":"521","article-title":"Recent developments in ADC technology: preclinical studies signal future clinical trends","volume":"31","author":"Drake","year":"2017","journal-title":"Bio-Drugs."},{"issue":"4","key":"R12-20241211","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs."},{"issue":"12","key":"R13-20241211","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"2","key":"R14-20241211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40259-013-0068-8","article-title":"CD30 as a therapeutic target for lymphoma","volume":"28","author":"Schirrmann","year":"2014","journal-title":"BioDrugs."},{"issue":"8","key":"R15-20241211","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood."},{"issue":"25","key":"R16-20241211","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood."},{"issue":"4","key":"R17-20241211","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"R18-20241211","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood."},{"issue":"3","key":"R19-20241211","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","article-title":"NCCN guidelines insights: Hodgkin lymphoma, version 1.2018","volume":"16","author":"Hoppe","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"30","key":"R20-20241211","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"R21-20241211","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood."},{"issue":"Supplement 1","key":"R22-20241211","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2018-99-115173","article-title":"A Phase II study of brentuximab vedotin plus Adriamycin and dacarbazine without radiation in non-bulky limited stage classical Hodgkin lymphoma","volume":"132","author":"Abramson","year":"2018","journal-title":"Blood"},{"key":"R23-20241211","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia","author":"Waldmann","year":"1993","journal-title":"Blood"},{"issue":"Supplement 1","key":"R24-20241211","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood"},{"key":"R25-20241211","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.61_2629","article-title":"Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT-301, CAMI) in relapsed\/refractory (r\/r) classical hodgkin lymphoma (CHL)","volume":"37","author":"Collins","year":"2019","journal-title":"Hematol Oncol"},{"issue":"9","key":"R26-20241211","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood."},{"issue":"6","key":"R27-20241211","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatric Blood Cancer."},{"issue":"8","key":"R28-20241211","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"R29-20241211","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"R30-20241211","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B- cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"R31-20241211","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"R32-20241211","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"R33-20241211","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"The Lancet Haematology."},{"issue":"1","key":"R34-20241211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Experimental hematology & oncology."},{"issue":"5","key":"R35-20241211","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019 s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"R36-20241211","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L- MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"R37-20241211","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hon.2437_33","article-title":"First clinical results of ADCT-402, a novel pyrrolo- benzodiazepine-based antibody drug conjugate (aDc), in relapsed\/refractory B-cell lineage NHL","volume":"35","author":"Kahl","year":"2017","journal-title":"Hematol Oncol"},{"issue":"8","key":"R38-20241211","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","article-title":"A phase II multicenter study of the anti- CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab- based immunotherapy","volume":"103","author":"Trn\u0115n\u00fd","year":"2018","journal-title":"Haematologica"},{"key":"R39-20241211","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.182.182","article-title":"A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed\/refactory B-lineage non-Hodgkin lymphoma","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"key":"R40-20241211","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7584","article-title":"A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT)","author":"Chen","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"R41-20241211","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bbamcr.2016.03.026","article-title":"The multifaceted roles of the invariant chain CD74\u2013More than just a chaperone","volume":"1863","author":"Schr\u00f6der","year":"2016","journal-title":"Biochimica et Bio- physica Acta-Molecular Cell Research"},{"issue":"18","key":"R42-20241211","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"102","key":"R43-20241211","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget."},{"key":"R44-20241211","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122754","article-title":"Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies","author":"Shah","year":"2019","journal-title":"Blood"},{"issue":"6","key":"R45-20241211","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/1535-7163.MCT-12-1170","article-title":"Milatuzumab\u2013SN-38 conjugates for the treatment of CD74+ cancers","volume":"12","author":"Govindan","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"R46-20241211","article-title":"Phase I\/II Study of hLL1-DOX in Relapsed NHL and CLL. NCT01585688"},{"issue":"5","key":"R47-20241211","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"issue":"9","key":"R48-20241211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2017.06.001","article-title":"The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models","volume":"19","author":"Hicks","year":"2017","journal-title":"Neoplasia."},{"issue":"5","key":"R49-20241211","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Invest New Drugs"},{"issue":"20","key":"R50-20241211","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T- cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood."},{"issue":"10168","key":"R51-20241211","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"The Lancet."},{"issue":"10094","key":"R52-20241211","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"The Lancet."},{"issue":"Supplement 1","key":"R53-20241211","first-page":"1509","article-title":"Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T- cell lymphoma (CTCL)","volume":"130","author":"Horwitz","year":"2017","journal-title":"Blood"},{"key":"R54-20241211","article-title":"Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL). NCT01925612"},{"issue":"18","key":"R55-20241211","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"R56-20241211","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood."},{"key":"R57-20241211","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hon.2437_79","article-title":"Pola-R-chp: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Tilly","year":"2017","journal-title":"Hematological Oncology."},{"key":"R58-20241211","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7505","article-title":"Polatuzumab vedotin (Pola)+ obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed\/refractory (R\/R) follicular lymphoma (FL): Interim analysis of a phase Ib\/II trial","author":"Diefenbach","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"R59-20241211","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.3324\/haematol.2019.233189","article-title":"Severe treatment-refractory T-cell- mediated immune skin toxicities observed with obinutuzu- mab\/rituximab-atezo-pola in two patients with follicular lymphoma","volume":"105","author":"Topp","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"R60-20241211","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14094","article-title":"A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non- Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy","volume":"174","author":"Goy","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"R61-20241211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/21556660.2017.1315336","article-title":"Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed\/refractory CD22+ B-cell non-Hodgkin lymphoma","volume":"6","author":"Sangha","year":"2017","journal-title":"Journal of drug assessment."},{"issue":"4","key":"R62-20241211","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"182","author":"Dang","year":"2018","journal-title":"Br J Haematol"},{"key":"R63-20241211","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7580","article-title":"A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL)","author":"Chung","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"R64-20241211","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood-2018-99-116081","article-title":"Interim results from the first-in-human clinical trial of Adct-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Radford","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"R65-20241211","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2019-128401","article-title":"Interim futility analysis of a phase 2 study of loncastuximab tesirine, a novel pyrrolobenzodiaze- pine-based antibody-drug conjugate, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"134","author":"Carlo-Stella","year":"2019","journal-title":"Blood"},{"key":"R66-20241211","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/hon.2438_143","article-title":"Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate in relapsed\/refractory hodgkin\/non-hodgkin lymphoma","volume":"35","author":"Horwitz","year":"2017","journal-title":"Hematological Oncology"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387621000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387621000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.07.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:29Z","timestamp":1787838509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.07.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2021.07.002","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2020-11-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}